What is the common examiner trap about Economy in UPSC exams?

Examiners may confuse the proposed trade markup cap (50-75%) with the past NPPA price cap on stents (70-85% reduction) — the former is a margin cap, the latter was a direct price cap. Also, the GST trigger point is the first point of sale, not the retail level.

What should UPSC aspirants remember about Economy for Prelims?

1. Target this Data: MRP inflation examples: pacemaker Rs 25,000→Rs 2 lakh, syringe Rs 3→Rs 30, heart valve Rs 4 lakh→Rs 26 lakh 2. Target this Nodal Body: National Pharmaceutical Pricing Authority (NPPA) under Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers 3. Target this Legal Point: Drugs (Prices Control) Order (DPCO) — the current pharma-centric pricing framework for medical devices

EconomyGovernance

Take AI Challenge ▸

News 13 of 21

NPPA Proposed Trade Markup Cap: 50-75% Margins for Medical Devices to Curb 10-30x MRP Inflation

Q: Which regulatory body is primarily responsible for fixing and revising prices of controlled drugs and medical devices under the Drugs (Prices Control) Order?

National Pharmaceutical Pricing Authority (NPPA), The National Pharmaceutical Pricing Authority (NPPA) is the independent regulatory body under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, responsible for implementing the DPCO and fixing/revising prices of scheduled drugs and medical devices.

Q: Consider the following statements regarding medical device pricing in India: 1. Medical devices in India are currently regulated under a separate pricing framework distinct from the Drugs (Prices Control) Order. 2. AiMeD has proposed a trade markup capping mechanism at the GST trigger point to ensure fair pricing. 3. The proposed pilot covers six categories of devices including pacemakers, heart valves, and syringes. Which of the statements given above is/are correct?

Both 2 and 3, Statement 1 is incorrect because medical devices are currently regulated under the Drugs (Prices Control) Order (DPCO), which is a pharma-centric framework, not a separate one. Statements 2 and 3 are correct as per the article: AiMeD proposed a trade markup cap at the GST trigger point, and the pilot covers six categories including pacemakers, heart valves, and syringes.

Q: According to the article, what was the price reduction achieved after NPPA capped stent prices in 2017?

70 to 85 per cent, The article explicitly states that NPPA capped stent prices in 2017, reducing costs by 70 to 85 per cent without any supply shortages. The other options are close distractors but only option C matches the exact range mentioned.

Q: What is the primary objective of the trade markup capping mechanism proposed by AiMeD for medical devices?

To protect patients from inflated MRPs while ensuring viability for manufacturers and distributors, The article highlights that the proposed mechanism aims to shield patients from irrational markups (10-30x inflation) while ensuring parity between domestic and overseas manufacturers and maintaining supply viability through calibrated margins. It does not aim to increase revenue, promote imports, or eliminate all profits.

Economy PolityCORE

Target:UPSC GS-IIIMPSCSSC GATeachingPrelims HighMains MediumStatic GK Link

20 Sept 2026

~2 min

Source: Indian Express

Key Data:MRP inflation: 10-30 timesPacemaker: Rs 25,000 to Rs 2 lakhSyringe: Rs 3 to Rs 30Heart valve: Rs 4 lakh to Rs 26 lakhProposed cap: 50% (>Rs 1 lakh), 66% (Rs 1,000-1 lakh), 75% (<Rs 1,000)Stent price cap 2017: 70-85% reduction

Bodies:NPPAMaharashtra FDAAiMeDDepartment of Pharmaceuticals

Practice MCQs from today's news ▸

~2 min · Quick mode

What This Article Covers

1.Maharashtra FDA flagged exploitative margins in medical devices, highlighting the need for a separate regulatory framework distinct from the Drugs (Prices Control) Order (DPCO).

2.Current MRPs are inflated 10-30 times above cost: pacemakers (Rs 25,000 to Rs 2 lakh), syringes (Rs 3 to Rs 30), heart valves (Rs 4 lakh to Rs 26 lakh).

3.AiMeD proposes a trade markup capping mechanism at the GST trigger point: 50% for devices above Rs 1 lakh, 66% for Rs 1,000-1 lakh, 75% for below Rs 1,000, with a 12-18 month pilot covering six device categories.

The Big Picture

Prelims · HighMains · Medium

India's medical device pricing, currently under drug-focused DPCO rules, allows MRPs inflated 10-30 times above cost. AiMeD proposes a trade markup cap at the GST trigger point (50-75% by price band) to ensure fair pricing, patient protection, and parity between domestic and import manufacturers.

Exam Lens

Quick Exam Facts From News

Current Pricing FrameworkDrugs (Prices Control) Order (DPCO) — pharma-centric

MRP Inflation ExamplesPacemaker: Rs 25,000 → Rs 2 lakh; Syringe: Rs 3 → Rs 30; Heart valve: Rs 4 lakh → Rs 26 lakh

Proposed Markup Caps50% (>Rs 1 lakh), 66% (Rs 1,000-1 lakh), 75% (<Rs 1,000)

Pilot Categories6 devices: pacemakers, heart valves, cardiac catheters, syringes, IV sets, intraocular lenses

Pilot Duration12-18 months

Advocating BodyAiMeD (Association of Indian Medical Device Industry)

Regulator Flagging IssueMaharashtra FDA Commissioner Tukaram Munde

Past Success: Stent Price CapNPPA capped stent prices in 2017, reducing costs by 70-85%

Past Success: Knee Implant CapPrices slashed by up to 69%

1-Minute Revision

›Current Pricing Framework: Drugs (Prices Control) Order (DPCO) — pharma-centric
›MRP Inflation Examples: Pacemaker: Rs 25,000 → Rs 2 lakh; Syringe: Rs 3 → Rs 30; Heart valve: Rs 4 lakh → Rs 26 lakh
›Target this Data: MRP inflation examples: pacemaker Rs 25,000→Rs 2 lakh, syringe Rs 3→Rs 30, heart valve Rs 4 lakh→Rs 26 lakh
›Target this Nodal Body: National Pharmaceutical Pricing Authority (NPPA) under Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers
›Target this Legal Point: Drugs (Prices Control) Order (DPCO) — the current pharma-centric pricing framework for medical devices

Mastered this topic? Test your knowledge with a full MCQ quiz.

Practice exam-style questions, track your score, and strengthen your recall.

News Snapshot

💉

Systemic MRP Distortion

Medical device MRPs are inflated 10-30 times above real costs due to drug-style pricing controls, with hospitals often choosing devices based on profit margins rather than patient welfare.

📊

Proposed Trade Markup Cap Model

AiMeD suggests capping trade margins at the GST trigger point by price band: 50% for devices above Rs 1 lakh, 66% for Rs 1,000-1 lakh, and 75% for devices below Rs 1,000.

🩺

Past Success & Pilot Plan

NPPA's stent (70-85% reduction) and knee implant (up to 69% reduction) caps prove price controls improve access; a 12-18 month pilot on 6 device categories is proposed.

Detailed Analysis & Strategic Depth

Context / Background

India's medical device sector has grown rapidly but remains regulated under the Drugs (Prices Control) Order (DPCO), designed for pharmaceuticals. The Medical Devices Rules, 2017 created a separate quality/safety framework, but pricing still uses drug-style controls, which fail to account for the diverse technology, costs, lifecycles, and supply chains of medical devices. This disconnect has led to systemic MRP inflation and a distorted market.

Core Analysis & Implications

The proposed trade markup capping at the GST trigger point (first point of sale) is a structural reform. It targets maximum transparency and creates a level playing field between domestic manufacturers (ex-factory price) and importers (landing price). The tiered caps (50%, 66%, 75%) are designed to ensure affordability for patients while maintaining viability for distributors. Past NPPA interventions on stents (70-85% reduction) and knee implants (up to 69% reduction) show that rational price caps improve access without causing shortages.

Future Outlook / Way Forward

AiMeD's proposal has been submitted to the NPPA Chairman and the Secretary of the Department of Pharmaceuticals. A 12-18 month pilot covering six device categories (pacemakers, heart valves, cardiac catheters, syringes, IV sets, intraocular lenses) is suggested. Regular review, stakeholder consultation, and calibrated margins are recommended to ensure supply continuity. With support from Maharashtra FDA and NPPA's past success, India is likely to move towards a distinct medical device pricing framework.

Key Facts at a Glance

Current Pricing FrameworkDrugs (Prices Control) Order (DPCO) — pharma-centric

MRP Inflation ExamplesPacemaker: Rs 25,000 → Rs 2 lakh; Syringe: Rs 3 → Rs 30; Heart valve: Rs 4 lakh → Rs 26 lakh

Proposed Markup Caps50% (>Rs 1 lakh), 66% (Rs 1,000-1 lakh), 75% (<Rs 1,000)

Pilot Categories6 devices: pacemakers, heart valves, cardiac catheters, syringes, IV sets, intraocular lenses

Pilot Duration12-18 months

Advocating BodyAiMeD (Association of Indian Medical Device Industry)

Regulator Flagging IssueMaharashtra FDA Commissioner Tukaram Munde

Past Success: Stent Price CapNPPA capped stent prices in 2017, reducing costs by 70-85%

Past Success: Knee Implant CapPrices slashed by up to 69%

You've read the full analysis. Now test your understanding.

Practice exam-style questions based on this article.

Q1Static LinkageEasyUPSC, SSC, Banking, State PSC

Which regulatory body is primarily responsible for fixing and revising prices of controlled drugs and medical devices under the Drugs (Prices Control) Order?

Q2Statement-basedHardUPSC, SSC

Consider the following statements regarding medical device pricing in India:

1. Medical devices in India are currently regulated under a separate pricing framework distinct from the Drugs (Prices Control) Order.

2. AiMeD has proposed a trade markup capping mechanism at the GST trigger point to ensure fair pricing.

3. The proposed pilot covers six categories of devices including pacemakers, heart valves, and syringes.

Which of the statements given above is/are correct?

Q3Data-centricMediumUPSC, SSC, Banking

According to the article, what was the price reduction achieved after NPPA capped stent prices in 2017?

Q4Application/ImpactMediumUPSC, SSC, Banking

What is the primary objective of the trade markup capping mechanism proposed by AiMeD for medical devices?

All 15 MCQs ▸

Read original article from Indian Express

You finished this topic

Practice 3 MCQs from this news Next Article

Explore Related Topics

EconomyView Topic MCQs →PolityView Topic MCQs →

PreviousPunjab Drug Menace: Policy Failure vs Slogans as 2027 Elections Approach Next India-New Zealand FTA Ratified, Implementation Set for October 20, 2026

Related Current Affairs

Polity Current Affairs

NPPA Raises Ceiling Prices of Cisplatin, Carboplatin by 50% Amid Shortage

India is in the grip of a critical nationwide shortage of cisplatin and carboplatin, two essential chemotherapy drugs, caused by a doubling in platinum prices and West Asia shipping disruptions. The NPPA has temporarily raised price caps by 50% to push manufacturers to restart production, making this a key case study on drug pricing regulation, public health preparedness, and supply-chain vulnerability for exams.

Polity Current Affairs

Tata Trusts’ 66% Stake & Affirmative Voting Rights under Articles 104B, 121: SC Verdict Explained

Tata Trusts, holding about 66% of Tata Sons, are challenging the reappointment of N Chandrasekaran as executive chairman, citing the affirmative voting rights of their nominee directors under the Articles of Association. The Supreme Court’s 2021 Tata-Mistry judgment upheld these special rights, making it the key legal backdrop to the current boardroom dispute. For exams, this news tests corporate governance, fiduciary duties, and the binding force of a company’s Articles.

Economy Current Affairs

India's QCO Reassessment: 88 to 765 Products Covered; Transition Facilitation Order 2026 for MSMEs

India rapidly expanded Quality Control Orders (QCOs) from 88 products (2019) to 765 (Dec 2024). A recent study reveals QCOs on inputs hurt MSME profitability by 47.6% and even larger firms' value addition. The 2026 Transition Facilitation Order aims to ease compliance, but reassessment of 600+ products remains critical for manufacturing competitiveness.

Economy Current Affairs

Anti-Dumping Duty on Chinese TiO2: DGTR Final Findings (Aug 3, 2026) - Centre Assures KMML, TTPL

The Centre has assured Kerala of imposing anti-dumping duty on Chinese titanium dioxide following DGTR's final findings. This protects PSUs like KMML and TTPL from low-cost imports. Key for Prelims: DGTR process, anti-dumping mechanism, and dates.

Economy Current Affairs

Make in India 12-Year Review: PLI Schemes Show Concentration, Manufacturing Growth Patchy

Make in India completes 12 years with mixed results: manufacturing growth has been inconsistent, PLI schemes attracted ₹2.4 lakh crore but concentrated in top 5 sectors, employment impact limited to 8.5 lakh direct jobs. Key data for exams: non-petroleum exports grew 53% to $388.3B, capacity utilisation remains below 80%.

Economy Current Affairs

ICAI Reviews CA Curriculum to Integrate AI, ESG, Forensic Auditing; Launches AURA 2.0 and International Programme

ICAI is overhauling the CA curriculum to include AI, data analytics, ESG, and forensic auditing to keep pace with global technological shifts. It is also developing an international CA programme for countries like Mauritius, Nepal, and African nations, and launching advanced AI training for members and students.

Economy Current Affairs

CBI Registers ₹1,816.22 Cr EPFO Investment Fraud Case Against Reliance Capital, Anil Ambani

The CBI has registered a major fraud case involving EPFO funds invested in Reliance Capital NCDs. This highlights issues of corporate governance, public sector investment safety, and regulatory oversight. For exams, focus on EPFO's investment norms, CBI's jurisdiction, and criminal provisions invoked.

Economy Current Affairs

CBDT's SAKSHAM NUDGE Campaign: ₹9,493 Cr Additional Tax from 1.25 Cr Updated ITRs

The CBDT's NUDGE campaign (now SAKSHAM NUDGE) has yielded ₹9,493 crore in additional tax from 1.25 crore updated ITRs in FY 2024-25 and 2025-26. This data-driven, non-intrusive compliance approach is a major shift from post-facto enforcement to preventive tax collection, a key theme for UPSC GS3 (Tax Reforms) and Banking exams.

Start Today's Quiz(15 Qs)

Take Today's Quiz

15 Qs • 5-7 Mins

NPPA Proposed Trade Markup Cap: 50-75% Margins for Medical Devices to Curb 10-30x MRP Inflation

Exam Lens

Quick Exam Facts From News

1-Minute Revision

News Snapshot

Systemic MRP Distortion

Proposed Trade Markup Cap Model

Past Success & Pilot Plan

Detailed Analysis & Strategic Depth

Context / Background

Core Analysis & Implications

Future Outlook / Way Forward

Prelims Flashpoints

Key Facts at a Glance